## Form 4

**United States Securities and Exchange Commission**  
Washington, D.C. 20549

### Statement of Changes in Beneficial Ownership of Securities

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. **Name and Address of Reporting Person**
   - GLOCER THOMAS H  
   - (Last)  
   - (First)  
   - (Middle)  
   - MERCK & CO., INC., 2000 GALLOPING HILL ROAD  
   - (Street)  
   - KENILWORTH, NJ 07033  
   - (City)  
   - (State)  
   - (Zip)

2. **Issuer Name and Ticker or Trading Symbol**
   - Merck & Co., Inc. [ MRK ]

3. **Date of Earliest Transaction (MM/DD/YYYY)**
   - 6/30/2021

4. **If Amendment, Date Original Filed (MM/DD/YYYY)**
   - 

5. **Relationship of Reporting Person(s) to Issuer**
   - Check all applicable
   - __X__ Director
   - _____ 10% Owner
   - _____ Officer (give title below)
   - _____ Other (specify below)

6. **Individual or Joint/Group Filing**
   - (Check Applicable Line)
   - _ Form filed by One Reporting Person
   - ___ Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>2. Trans. Date</th>
<th>2A. Deemed Execution Date, if any</th>
<th>3. Trans. Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Trans. Date</th>
<th>3A. Deemed Execution Date, if any</th>
<th>4. Trans. Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)</th>
<th>6. Date Exercisable and Expiration Date</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phantom Stock</td>
<td>(1)</td>
<td>6/30/2021</td>
<td>A</td>
<td>112.5113</td>
<td>(2)</td>
<td>(2)</td>
<td>Common Stock 112.5113 $77.77 78357.7946 Unit(d)</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

(1) 1-for-1

(2) Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

(3) Holdings include shares acquired in dividend reinvestment transactions.

(4) Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by each award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.

### Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLOCER THOMAS H</td>
<td>Director 10% Owner Officer Other</td>
</tr>
<tr>
<td>MERCK &amp; CO., INC.</td>
<td></td>
</tr>
<tr>
<td>2000 GALLOPING HILL ROAD</td>
<td></td>
</tr>
<tr>
<td>KENILWORTH, NJ 07033</td>
<td></td>
</tr>
</tbody>
</table>

**Signatures**

/s/ Kelly E. W. Grez as Attorney-in-Fact for Thomas H. Glocer  
7/2/2021  
Signature of Reporting Person  
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.